Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter Veterinary (8) Apply Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Withdrawn applications Remove Withdrawn applications filter Paediatric investigation plans Remove Paediatric investigation plans filter Referrals Remove Referrals filter Direct healthcare professional communication Remove Direct healthcare professional communication filter Summaries of opinion (21) Apply Summaries of opinion filter Orphan designations (135) Apply Orphan designations filter

Product number

Patient safety

Yes (10) Apply Yes filter

Authorisation status

Authorised (414) Apply Authorised filter Refused (3) Apply Refused filter Withdrawn (59) Apply Withdrawn filter

ATC code

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

Withdrawal type

Initial authorisation (6) Apply Initial authorisation filter Post-authorisation (9) Apply Post-authorisation filter

Withdrawal date

From:

To:

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (17) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (160) Apply PM: decision on the application for modification of an agreed PIP filter RPM: decision refers to a refusal on the application for modification of an agreed PIP (1) Apply RPM: decision refers to a refusal on the application for modification of an agreed PIP filter RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) (1) Apply RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) filter W: decision granting a waiver in all age groups for all conditions or indications (36) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (26) Apply Yes filter

Compliance procedure number

Referral name

Referral status

European Commission final decision (15) Apply European Commission final decision filter Procedure started (1) Apply Procedure started filter

Referral safety status

Yes (7) Apply Yes filter

Referral type

Article 20 procedures (12) Apply Article 20 procedures filter Article 31 referrals (4) Apply Article 31 referrals filter

Referral reference number

Referral decision making model

PRAC-CAT-CHMP-EC (1) Apply PRAC-CAT-CHMP-EC filter PRAC-CHMP-EC (12) Apply PRAC-CHMP-EC filter

Referral authorisation model

Centrally and nationally authorised products (mixed) (4) Apply Centrally and nationally authorised products (mixed) filter Centrally authorised product(s) (12) Apply Centrally authorised product(s) filter

Referral PRAC recommendation

Risk minimisation measures (10) Apply Risk minimisation measures filter Suspension (2) Apply Suspension filter

Referral procedure start date

From:

To:

Referral PRAC recommendation date

From:

To:

Medicine type

Accelerated assessment Remove Accelerated assessment filter Additional monitoring Remove Additional monitoring filter Biosimilar Remove Biosimilar filter Conditional approval Remove Conditional approval filter Exceptional circumstances Remove Exceptional circumstances filter Generic (322) Apply Generic filter Orphan medicine (309) Apply Orphan medicine filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

759 results

Remove all filtersRemove all filters

Categories Human Remove Human filter

Medicine type Accelerated assessment Remove Accelerated assessment filter Conditional approval Remove Conditional approval filter Additional monitoring Remove Additional monitoring filter Exceptional circumstances Remove Exceptional circumstances filter Biosimilar Remove Biosimilar filter

Medicine Paediatric investigation plans Remove Paediatric investigation plans filter European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Direct healthcare professional communication Remove Direct healthcare professional communication filter Withdrawn applications Remove Withdrawn applications filter Referrals Remove Referrals filter

Sort by

List item

Human medicine European public assessment report (EPAR): Brukinsa (updated)

zanubrutinib, Waldenstrom Macroglobulinemia
Date of authorisation: 22/11/2021, , Revision: 5, Authorised, Last updated: 24/03/2023
List item

Human medicine European public assessment report (EPAR): Truvelog Mix 30 (updated)

insulin aspart, Diabetes Mellitus
Date of authorisation: 25/04/2022, , , Revision: 1, Authorised, Last updated: 23/03/2023
List item

Human medicine European public assessment report (EPAR): Terrosa (updated)

teriparatide, Osteoporosis
Date of authorisation: 04/01/2017, , , Revision: 6, Authorised, Last updated: 23/03/2023
List item

Human medicine European public assessment report (EPAR): Upstaza (updated)

Eladocagene exuparvovec, Amino Acid Metabolism, Inborn Errors
Date of authorisation: 18/07/2022, , , , Revision: 3, Authorised, Last updated: 23/03/2023
List item

Human medicine European public assessment report (EPAR): Vegzelma (updated)

bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 17/08/2022, , , Revision: 2, Authorised, Last updated: 22/03/2023
List item

Human medicine European public assessment report (EPAR): Polivy (updated)

polatuzumab vedotin, Lymphoma, B-Cell
Date of authorisation: 16/01/2020, , , , Revision: 5, Authorised, Last updated: 22/03/2023
List item

Human medicine European public assessment report (EPAR): Zynlonta (updated)

loncastuximab tesirine, Lymphoma, Large B-Cell, Diffuse; Lymphoma, B-Cell
Date of authorisation: 20/12/2022, , , Revision: 1, Authorised, Last updated: 22/03/2023
List item

Human medicine European public assessment report (EPAR): Blincyto (updated)

blinatumomab, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 23/11/2015, , , Revision: 16, Authorised, Last updated: 22/03/2023
List item

Human medicine European public assessment report (EPAR): PreHevbri (updated)

hepatitis B surface antigen, Hepatitis B
Date of authorisation: 25/04/2022, , Revision: 1, Authorised, Last updated: 22/03/2023
List item

Human medicine European public assessment report (EPAR): Darzalex (updated)

Daratumumab, Multiple Myeloma
Date of authorisation: 20/05/2016, , , Revision: 20, Authorised, Last updated: 22/03/2023
List item

Human medicine European public assessment report (EPAR): Insulin lispro Sanofi (updated)

insulin lispro, Diabetes Mellitus
Date of authorisation: 19/07/2017, , Revision: 8, Authorised, Last updated: 22/03/2023
List item

Human medicine European public assessment report (EPAR): Herzuma (updated)

trastuzumab, Stomach Neoplasms; Breast Neoplasms
Date of authorisation: 09/02/2018, , Revision: 19, Authorised, Last updated: 22/03/2023
List item

Human medicine European public assessment report (EPAR): Ultomiris (updated)

ravulizumab, Hemoglobinuria, Paroxysmal
Date of authorisation: 02/07/2019, , Revision: 10, Authorised, Last updated: 22/03/2023
List item

Human medicine European public assessment report (EPAR): Imcivree (updated)

Setmelanotide, Obesity
Date of authorisation: 16/07/2021, , , Revision: 7, Authorised, Last updated: 22/03/2023
List item

Human medicine European public assessment report (EPAR): Vihuma (updated)

simoctocog alfa, Hemophilia A
Date of authorisation: 13/02/2017, , Revision: 8, Authorised, Last updated: 21/03/2023
List item

Human medicine European public assessment report (EPAR): Beyfortus (updated)

nirsevimab,
Date of authorisation: 31/10/2022, , Revision: 1, Authorised, Last updated: 21/03/2023
List item

Human medicine European public assessment report (EPAR): Inrebic (updated)

fedratinib dihydrochloride monohydrate, Myeloproliferative Disorders; Primary Myelofibrosis
Date of authorisation: 08/02/2021, , , Revision: 4, Authorised, Last updated: 21/03/2023
List item

Human medicine European public assessment report (EPAR): Vydura (updated)

Rimegepant, Migraine Disorders
Date of authorisation: 25/04/2022, , Revision: 4, Authorised, Last updated: 21/03/2023
List item

Human medicine European public assessment report (EPAR): Flucelvax Tetra (updated)

A/Wisconsin/588/2019 (H1N1)pdm09-like strain (A/Delaware/55/2019 CVR-45) A/Darwin/6/2021 (H3N2)-like strain (A/Darwin/11/2021, wild type) B/Austria/1359417/2021-like strain (B/Singapore/WUH4618/2021, wild type) B/Phuket/3073/2013-like strain (B/Singapore/INFTT-16-0610/2016, wild type), Influenza, Human
Date of authorisation: 12/12/2018, , Revision: 12, Authorised, Last updated: 21/03/2023
List item

Human medicine European public assessment report (EPAR): Reblozyl (updated)

Luspatercept, Anemia; Myelodysplastic Syndromes; beta-Thalassemia
Date of authorisation: 25/06/2020, , , Revision: 4, Authorised, Last updated: 20/03/2023
List item

Human medicine European public assessment report (EPAR): Nubeqa (updated)

darolutamide, Prostatic Neoplasms, Castration-Resistant
Date of authorisation: 27/03/2020, , Revision: 4, Authorised, Last updated: 20/03/2023
List item

Human medicine European public assessment report (EPAR): Isturisa (updated)

Osilodrostat phosphate, Cushing Syndrome
Date of authorisation: 09/01/2020, , , Revision: 4, Authorised, Last updated: 20/03/2023
List item

Human medicine European public assessment report (EPAR): Vaxzevria (previously COVID-19 Vaccine AstraZeneca) (updated)

ChAdOx1-SARS-COV-2, COVID-19 virus infection
Date of authorisation: 29/01/2021, , , Revision: 27, Authorised, Last updated: 20/03/2023
List item

Human medicine European public assessment report (EPAR): Erleada (updated)

apalutamide, Prostatic Neoplasms
Date of authorisation: 14/01/2019, , Revision: 9, Authorised, Last updated: 20/03/2023
List item

Human medicine European public assessment report (EPAR): Quviviq (updated)

daridorexant hydrochloride, Sleep Initiation and Maintenance Disorders
Date of authorisation: 29/04/2022, , Revision: 4, Authorised, Last updated: 17/03/2023